TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The SIMPLIFIED trial found that 60,000 IU of vitamin D3 every two weeks did not significantly improve overall survival for adults receiving dialysis, compared with standard care. Researchers reported exploratory signals in some subgroups, but said those results are not definitive and do not support routine high-dose supplementation.
A large U.K. trial found that high-dose vitamin D3 did not significantly improve overall survival among adults receiving dialysis for end-stage kidney disease. In the SIMPLIFIED study, 3,866 patients assigned to 60,000 IU of cholecalciferol every two weeks had survival outcomes similar to patients receiving standard care without trial supplementation, according to results presented at the American Society of Nephrology’s Kidney Week meeting.
After a median 7.5 years of follow-up, the trial reported a conditional hazard ratio for death of 0.95 (95% confidence interval 0.86-1.04; P=0.26). The result did not show a statistically significant survival difference between the groups. There were 1,817 deaths during the study. Sensitivity analyses accounting for kidney transplantation, COVID-19 infection and stopping treatment did not change the primary result.
The study also found no significant differences in its listed secondary outcomes: fatal and nonfatal cardiovascular events, infections, fractures and malignancy. At least one hospital admission occurred in 69% of participants in the vitamin D group and 70% of those receiving standard care. Researchers described the high-dose treatment as safe and well tolerated in the trial.
Vitamin D levels rose substantially in the supplemented group in an early assessment of 206 participants: after four months, median plasma 25-hydroxyvitamin D was 141 nmol/L, compared with 36.5 nmol/L in the control group. That increase in measured vitamin D did not translate into a significant survival advantage in the full trial population.
What the Trial Means for Dialysis Care
The findings challenge the assumption that correcting or raising vitamin D levels with a high-dose regimen will improve survival for dialysis patients. The study is relevant because people receiving dialysis face substantial long-term health risks, and vitamin D deficiency is common in this population. However, the trial tested a particular supplementation strategy against standard care; it does not establish that vitamin D has no role in every patient or that clinically identified deficiency should be left untreated.
For clinicians and patients, the central takeaway is narrower: the results do not support routinely giving this high dose to all dialysis patients to extend life. The study did not find significant differences in several major health outcomes, either. Individual decisions about testing and replacement remain distinct from the question of whether population-wide high-dose supplementation improves survival.
Products Worth Considering
LEVOIT Vital 200S-P Smart Air Purifier for Large Rooms
Oral-B iO Series 7 Rechargeable Electric Toothbrush with 2 Brush Heads and Charging Travel Case
Levoit Core 600S-P Smart Air Purifier for Large Rooms
As an affiliate, we earn on qualifying purchases.
Why Researchers Tested Vitamin D
SIMPLIFIED was designed to address limited evidence on whether vitamin D supplementation changes clinical outcomes in people with advanced kidney disease. The report notes that observational research has linked low vitamin D levels with higher mortality and other adverse outcomes, but such associations do not show that supplementation causes better outcomes.
Guidelines from Kidney Disease: Improving Global Outcomes suggest measuring 25-hydroxyvitamin D in people with stage 3-5 chronic kidney disease, including those on dialysis, and replacing it when levels are deficient. Trial investigator Rona Smith said the guideline recommendation recognizes that the supporting evidence is low grade. The pragmatic trial enrolled patients at 55 U.K. renal units; 94% were receiving in-center hemodialysis, and the median time on dialysis at baseline was 2.25 years.
Limits of Subgroup Signals
Prespecified subgroup analyses suggested a possible benefit among men and non-white participants, but the trial was not powered to establish effects in those groups. Smith said the results should be treated as hypothesis-generating, not definitive. The report does not establish whether future research will confirm a benefit for either subgroup or identify which patients, if any, might benefit.
A nominal reduction in overall major adverse cardiovascular events was also reported (hazard ratio 0.88, 95% CI 0.78-0.99; P=0.03), driven mainly by fewer peripheral arterial disease events (hazard ratio 0.80, 95% CI 0.65-0.99; P=0.04). Smith cautioned that the study was not powered to confirm findings for those individual outcomes. These secondary signals do not overturn the non-significant primary survival result.
Further Trials Must Test Signals
The reported results point to a need for further research before subgroup or cardiovascular findings can guide practice. Future studies could test whether patients with lower baseline vitamin D levels, including some non-white patients, respond differently, but the current report does not specify a planned follow-up trial or timeline. For now, the evidence presented supports caution about using 60,000 IU every two weeks as routine survival-improving treatment for dialysis patients.
Key Questions
Did high-dose vitamin D improve survival in the trial?
No. The SIMPLIFIED trial found no statistically significant difference in overall survival between patients given 60,000 IU of vitamin D3 every two weeks and those receiving standard care.
How many patients took part, and how long were they followed?
The trial randomized 3,866 adults receiving dialysis at 55 U.K. renal units. Median follow-up was 7.5 years.
Did the study show vitamin D should never be used in dialysis patients?
No. The findings do not support routine use of this high-dose regimen to improve survival. They do not answer every question about testing for deficiency or treating an individual patient. Clinical decisions should be made with a health professional.
What did researchers find for men and non-white patients?
Subgroup analyses suggested a possible benefit, but researchers said the study was not powered to confirm those findings. They should be treated as preliminary rather than proof of benefit.
Source: medpagetoday.com
